VISTA Trial
NOW ENROLLING!! We are now screening for a phase 2/3 clinical trial for X-Linked Retinitis Pigmentosa. Learn more about the clinical trial or how to qualify for no-cost genetic testing and/or prescreening.
We are an ophthalmic gene therapy company founded to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
Bold science
AAV Gene Therapy
Gene therapy for ophthalmic disorders
Gene therapy is the process of modifying a patient’s cells by adding a functional copy of the mutated gene responsible for the disease. The new functional copy allows a patient’s own body to produce proteins to treat or prevent genetic conditions. A single treatment can provide long lasting benefits, potentially leading to a better quality of life.
Join us
Make Remarkable Happen
Beacon Therapeutics is always seeking new talent to join our teams and help deliver our mission to save and restore vision to patients with blinding retinal diseases.
If you are interested in joining our team and have the passion, skills and motivation to be a part of this transformational science, then we are keen to hear from you. Please refer to our careers information.
“X-linked retinitis pigmentosa is arguably the most common of the severe forms of genetic blindness. It begins in early childhood and affects people worldwide. Gradual loss of peripheral vision leads to complete blindness and in the prime of life. It is the most devastating of eye diseases, but gene therapy offers a real hope of a lasting treatment, with recent studies reporting significant gains in vision in clinical trials.”
Professor Robert MacLaren
Professor of Ophthalmology, University of Oxford and Co-Founder of Beacon Therapeutics